+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
General Anesthesia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
General Anesthesia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

General Anesthesia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 210 Pages
  • January 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 6050342
Description Jump to:
The global General Anesthesia Drugs market is anticipated to expand at a steady CAGR of 3.44%, reaching a projected market value of USD 5.43 billion in 2025 and USD 6.89 billion by 2032. The increasing prevalence of chronic diseases and rising demand for surgical procedures worldwide are driving market expansion.

Market Insights General anesthesia drugs are essential for medical procedures that require unconsciousness and loss of protective reflexes. These drugs, administered intravenously or via inhalation, include Propofol, Etomidate, Ketamine, Sevoflurane, and Desflurane. The growing demand for surgeries such as cardiac procedures, orthopedic replacements, and cancer treatments is fueling the growth of this market.

Market Growth Drivers

1. Increasing Frequency of Surgeries: Rising cases of cardiovascular diseases, cancer, and osteoarthritis have led to a higher number of surgeries, thereby driving demand for general anesthesia drugs.

2. Continuous Approval of New Anesthetic Drugs: The introduction of innovative and effective anesthesia drugs ensures better patient safety and improved surgical outcomes.

3. Rising Investments in Pharmaceutical R&D: Governments and private organizations are heavily investing in the pharmaceutical manufacturing sector, boosting the availability of anesthesia drugs.

4. Demand for Inhalation Anesthesia: Inhalation anesthesia drugs are gaining traction due to their efficiency and safety profile, further contributing to market growth.

Business Opportunities

1. Adoption of Ambulatory Anesthesia: Ambulatory anesthesia is enabling faster patient recovery and reducing hospital stays, providing growth opportunities for market players.

2. Increasing Drug Approvals: Regulatory approvals for new anesthesia drugs enhance market competitiveness and expand product offerings.

3. Technological Advancements: Innovations in anesthesia drug formulations and delivery methods are set to drive market growth.

Market Restraints

1. Side Effects and Complications: Anesthetic drugs can cause nausea, vomiting, respiratory issues, and potential neurotoxicity, which may hinder market growth.

2. Risks in Pediatric and Pregnant Patients: Special caution is needed while administering anesthesia to infants and pregnant women due to potential adverse effects, limiting its use in specific patient groups.

Regional Analysis

1. North America: The region leads the market due to a high number of surgeries, strong healthcare infrastructure, and continuous drug development.

2. Europe: Increasing aging population and the rising prevalence of chronic diseases drive market demand.

3. Asia Pacific: The surge in cosmetic surgeries, particularly in China, and an increasing number of cardiovascular patients present significant growth opportunities.

4. Latin America & Middle East & Africa: Gradual improvements in healthcare infrastructure and rising healthcare expenditure are expected to support market expansion.

Competitive Analysis Prominent market players are investing in research and development, product innovation, and strategic partnerships to expand their presence. Key companies in the general anesthesia drugs market include:
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals PLC
  • Abbott Laboratories
  • Avet Pharmaceuticals, Inc.
  • Piramal Enterprises Limited
  • Teva Pharmaceuticals
  • Viatris/Mylan
  • Novartis AG
  • GlaxoSmithKline PLC
  • Sanofi
  • Gilead Sciences, Inc.
  • Akorn
  • Apotex

Recent Developments

1. Hikma Pharmaceuticals launched Midazolam injection pouches in June 2023, approved for continuous intravenous infusion to provide sedation.

2. Sedana Medical AB introduced Sedaconda (Isoflurane) in Germany in February 2022, expanding the range of available anesthesia products.

Market Segmentation

  • By Drug Class: Propofol, Sevoflurane, Dexmedetomidine, Desflurane, Remifentanil, Midazolam, Others.
  • By Route of Administration: Intravenous Anesthesia, Inhaled Anesthesia.
  • By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics.
  • By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global General Anesthesia Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Volume and Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact Of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. Pestle Analysis
3. Production Output and Trade Statistics, 2019 - 2024
3.1. Global General Anesthesia Drugs Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2024
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2019 - 2024
4.1. Global Average Price Analysis, by Drug Class, US$ Per Unit, 2019 - 2024
4.2. Prominent Factor Affecting General Anesthesia Drugs Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2024
5. Global General Anesthesia Drugs Market Outlook, 2019 - 2032
5.1. Global General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Propofol
5.1.1.2. Sevoflurane
5.1.1.3. Dexmedetomidine
5.1.1.4. Desflurane
5.1.1.5. Remifentanil
5.1.1.6. Midazolam
5.1.1.7. Others
5.2. Global General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Intravenous Anesthesia
5.2.1.2. Inhaled Anesthesia
5.3. Global General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Ambulatory Surgical Centers
5.3.1.3. Specialty Clinics
5.4. Global General Anesthesia Drugs Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
5.4.1. Key Highlights
5.4.1.1. North America
5.4.1.2. Europe
5.4.1.3. Asia Pacific
5.4.1.4. Latin America
5.4.1.5. Middle East & Africa
6. North America General Anesthesia Drugs Market Outlook, 2019 - 2032
6.1. North America General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Propofol
6.1.1.2. Sevoflurane
6.1.1.3. Dexmedetomidine
6.1.1.4. Desflurane
6.1.1.5. Remifentanil
6.1.1.6. Midazolam
6.1.1.7. Others
6.2. North America General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Intravenous Anesthesia
6.2.1.2. Inhaled Anesthesia
6.3. North America General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Ambulatory Surgical Centers
6.3.1.3. Specialty Clinics
6.4. North America General Anesthesia Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1. Key Highlights
6.4.1.1. U.S. General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1.2. U.S. General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1.3. U.S. General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1.4. Canada General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1.5. Canada General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.1.6. Canada General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
6.4.2. Market Attractiveness Analysis
7. Europe General Anesthesia Drugs Market Outlook, 2019 - 2032
7.1. Europe General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Propofol
7.1.1.2. Sevoflurane
7.1.1.3. Dexmedetomidine
7.1.1.4. Desflurane
7.1.1.5. Remifentanil
7.1.1.6. Midazolam
7.1.1.7. Others
7.2. Europe General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Intravenous Anesthesia
7.2.1.2. Inhaled Anesthesia
7.3. Europe General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Ambulatory Surgical Centers
7.3.1.3. Specialty Clinics
7.4. Europe General Anesthesia Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1. Key Highlights
7.4.1.1. Germany General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.2. Germany General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.3. Germany General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.4. U.K. General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.5. U.K. General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.6. U.K. General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.7. France General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.8. France General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.9. France General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.10. Italy General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.11. Italy General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.12. Italy General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.13. Turkey General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.14. Turkey General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.15. Turkey General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.16. Russia General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.17. Russia General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.18. Russia General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.19. Rest Of Europe General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.20. Rest Of Europe General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.1.21. Rest of Europe General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
7.4.2. Market Attractiveness Analysis
8. Asia Pacific General Anesthesia Drugs Market Outlook, 2019 - 2032
8.1. Asia Pacific General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Propofol
8.1.1.2. Sevoflurane
8.1.1.3. Dexmedetomidine
8.1.1.4. Desflurane
8.1.1.5. Remifentanil
8.1.1.6. Midazolam
8.1.1.7. Others
8.2. Asia Pacific General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Intravenous Anesthesia
8.2.1.2. Inhaled Anesthesia
8.3. Asia Pacific General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Ambulatory Surgical Centers
8.3.1.3. Specialty Clinics
8.4. Asia Pacific General Anesthesia Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1. Key Highlights
8.4.1.1. China General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.2. China General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.3. China General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.4. Japan General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.5. Japan General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.6. Japan General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.7. South Korea General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.8. South Korea General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.9. South Korea General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.10. India General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.11. India General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.12. India General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.13. Southeast Asia General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.14. Southeast Asia General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.15. Southeast Asia General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.16. Rest Of Asia Pacific General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.17. Rest Of Asia Pacific General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.1.18. Rest of Asia General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
8.4.2. Market Attractiveness Analysis
9. Latin America General Anesthesia Drugs Market Outlook, 2019 - 2032
9.1. Latin America General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.1.1. Key Highlights
9.1.1.1. Propofol
9.1.1.2. Sevoflurane
9.1.1.3. Dexmedetomidine
9.1.1.4. Desflurane
9.1.1.5. Remifentanil
9.1.1.6. Midazolam
9.1.1.7. Others
9.2. Latin America General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.2.1. Key Highlights
9.2.1.1. Intravenous Anesthesia
9.2.1.2. Inhaled Anesthesia
9.3. Latin America General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.3.1. Key Highlights
9.3.1.1. Hospitals
9.3.1.2. Ambulatory Surgical Centers
9.3.1.3. Specialty Clinics
9.4. Latin America General Anesthesia Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1. Key Highlights
9.4.1.1. Brazil General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.2. Brazil General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.3. Brazil General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.4. Mexico General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.5. Mexico General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.6. Mexico General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.7. Argentina General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.8. Argentina General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.9. Argentina General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.10. Rest Of Latin America General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.11. Rest Of Latin America General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.1.12. Rest of Latin America General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
9.4.2. Market Attractiveness Analysis
10. Middle East & Africa General Anesthesia Drugs Market Outlook, 2019 - 2032
10.1. Middle East & Africa General Anesthesia Drugs Market Outlook, by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.1.1. Key Highlights
10.1.1.1. Propofol
10.1.1.2. Sevoflurane
10.1.1.3. Dexmedetomidine
10.1.1.4. Desflurane
10.1.1.5. Remifentanil
10.1.1.6. Midazolam
10.1.1.7. Others
10.2. Middle East & Africa General Anesthesia Drugs Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.2.1. Key Highlights
10.2.1.1. Intravenous Anesthesia
10.2.1.2. Inhaled Anesthesia
10.3. Middle East & Africa General Anesthesia Drugs Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.3.1. Key Highlights
10.3.1.1. Hospitals
10.3.1.2. Ambulatory Surgical Centers
10.3.1.3. Specialty Clinics
10.4. Middle East & Africa General Anesthesia Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1. Key Highlights
10.4.1.1. GCC General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.2. GCC General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.3. GCC General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.4. South Africa General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.5. South Africa General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.6. South Africa General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.7. Egypt General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.8. Egypt General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.9. Egypt General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.10. Nigeria General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.11. Nigeria General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.12. Nigeria General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.13. Rest Of Middle East & Africa General Anesthesia Drugs Market by Drug Class, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.14. Rest Of Middle East & Africa General Anesthesia Drugs Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.1.15. Rest of Middle East & Africa General Anesthesia Drugs Market by End User, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
10.4.2. Market Attractiveness Analysis
11. Competitive Landscape
11.1. By Route of Administration Vs by Consumer Orientation Heat Map
11.2. Manufacturer Vs by Consumer Orientation Heatmap
11.3. Company Market Share Analysis, 2025
11.4. Competitive Dashboard
11.5. Company Profiles
11.5.1. Baxter International Inc.
11.5.1.1. Company Overview
11.5.1.2. Drug Class Portfolio
11.5.1.3. Financial Overview
11.5.1.4. Business Strategies and Development
11.5.2. AstraZeneca
11.5.2.1. Company Overview
11.5.2.2. Drug Class Portfolio
11.5.2.3. Financial Overview
11.5.2.4. Business Strategies and Development
11.5.3. AbbVie Inc.
11.5.3.1. Company Overview
11.5.3.2. Drug Class Portfolio
11.5.3.3. Financial Overview
11.5.3.4. Business Strategies and Development
11.5.4. B. Braun Melsungen AG
11.5.4.1. Company Overview
11.5.4.2. Drug Class Portfolio
11.5.4.3. Financial Overview
11.5.4.4. Business Strategies and Development
11.5.5. Fresenius SE & Co. KgaA
11.5.5.1. Company Overview
11.5.5.2. Drug Class Portfolio
11.5.5.3. Financial Overview
11.5.5.4. Business Strategies and Development
11.5.6. Pfizer
11.5.6.1. Company Overview
11.5.6.2. Drug Class Portfolio
11.5.6.3. Financial Overview
11.5.6.4. Business Strategies and Development
11.5.7. Hospira Inc.
11.5.7.1. Company Overview
11.5.7.2. Drug Class Portfolio
11.5.7.3. Financial Overview
11.5.7.4. Business Strategies and Development
11.5.8. Aspen Pharmacare Holdings Limited
11.5.8.1. Company Overview
11.5.8.2. Drug Class Portfolio
11.5.8.3. Financial Overview
11.5.8.4. Business Strategies and Development
11.5.9. Hikama Pharmaceuticals plc
11.5.9.1. Company Overview
11.5.9.2. Drug Class Portfolio
11.5.9.3. Financial Overview
11.5.9.4. Business Strategies and Development
11.5.10. Abbott Laboratories
11.5.10.1. Company Overview
11.5.10.2. Drug Class Portfolio
11.5.10.3. Financial Overview
11.5.10.4. Business Strategies and Development
11.5.11. Avet Pharmaceuticals, Inc
11.5.11.1. Company Overview
11.5.11.2. Drug Class Portfolio
11.5.11.3. Financial Overview
11.5.11.4. Business Strategies and Development
11.5.12. Piramal Enterprises Limited
11.5.12.1. Company Overview
11.5.12.2. Drug Class Portfolio
11.5.12.3. Financial Overview
11.5.12.4. Business Strategies and Development
11.5.13. Par Pharmaceutical
11.5.13.1. Company Overview
11.5.13.2. Drug Class Portfolio
11.5.13.3. Financial Overview
11.5.13.4. Business Strategies and Development
11.5.14. Teva Pharmaceuticals
11.5.14.1. Company Overview
11.5.14.2. Drug Class Portfolio
11.5.14.3. Financial Overview
11.5.14.4. Business Strategies and Development
11.5.15. Viatris/Mylan
11.5.15.1. Company Overview
11.5.15.2. Drug Class Portfolio
11.5.15.3. Financial Overview
11.5.15.4. Business Strategies and Development
11.5.16. Novartis AG
11.5.16.1. Company Overview
11.5.16.2. Drug Class Portfolio
11.5.16.3. Financial Overview
11.5.16.4. Business Strategies and Development
11.5.17. GlaxoSmithKline plc
11.5.17.1. Company Overview
11.5.17.2. Drug Class Portfolio
11.5.17.3. Financial Overview
11.5.17.4. Business Strategies and Development
11.5.18. Gilead Sciences, Inc.
11.5.18.1. Company Overview
11.5.18.2. Drug Class Portfolio
11.5.18.3. Financial Overview
11.5.18.4. Business Strategies and Development
11.5.19. Sanofi
11.5.19.1. Company Overview
11.5.19.2. Drug Class Portfolio
11.5.19.3. Financial Overview
11.5.19.4. Business Strategies and Development
11.5.20. Akorn
11.5.20.1. Company Overview
11.5.20.2. Drug Class Portfolio
11.5.20.3. Financial Overview
11.5.20.4. Business Strategies and Development
11.5.21. Apotex
11.5.21.1. Company Overview
11.5.21.2. Drug Class Portfolio
11.5.21.3. Financial Overview
11.5.21.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms And Abbreviations

Companies Mentioned

  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories
  • Avet Pharmaceuticals, Inc
  • Piramal Enterprises Limited
  • Par Pharmaceutical
  • Teva Pharmaceuticals
  • Viatris/Mylan
  • Novartis AG
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Sanofi
  • Akorn
  • Apotex

Methodology

Loading
LOADING...

Related Topics

Related Reports

Local Anesthesia Drugs Market Report by Drug Type, Mode of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Local Anesthesia Drugs Market Report by Drug Type, Mode of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Anesthesia Ultrasound Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Anesthesia Ultrasound Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 205 Pages
  • Global
From
Inhalation Anesthesia Market Report by Product, Application, End User, and Region 2024-2032 - Product Image

Inhalation Anesthesia Market Report by Product, Application, End User, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Anesthesia Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Anesthesia Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
General Anesthesia Drugs - Global Strategic Business Report - Product Image

General Anesthesia Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.